# Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal

Source: https://onco.cc/trials/nct06252649/  
OnCo record `nct06252649` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Sotorasib, Panitumumab in colorectal cancer, run by Amgen, now recruiting.

## Summary

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation is a phase 3 interventional study registered as NCT06252649 by Amgen, with 450 participants planned, started 2024-07-17 and due to reach its primary completion in 2028-09-25. Interventions recorded: FOLFIRI Regimen, Sotorasib, Panitumumab, Bevacizumab-awwb. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06252649
- Phase: 3
- Setting: Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)
- Sponsor: Amgen
- Enrolled: 450

## Sources

- ClinicalTrials.gov NCT06252649: https://clinicaltrials.gov/study/NCT06252649

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Panitumumab](https://onco.cc/drugs/panitumumab/), [Sotorasib](https://onco.cc/drugs/sotorasib/)
- companies: [Amgen](https://onco.cc/companies/amgen/)

---
JSON: https://onco.cc/api/v1/entities/nct06252649.json